- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06081634
Study Efficacy of Enhancing Cognitive Reserve in Patients With a First Bipolar Episode
Study on the Efficacy of a Psychological Approach for the Enhancement of Cognitive Reserve in a Bipolar Population With a Recent First Episode
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients between 18 and 40 years of age whose disease onset (first episode) is within the last 5 years.
- Fulfill diagnostic criteria for bipolar disorder (type I or type II) or schizoaffective disorder, bipolar type, according to the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (DSM-5) based on a semi-structured clinical interview.
- Patients in clinical remission or partial remission at the time of assessment, defined as scores ≤ 10 on the Young Mania Rating Scale (YMRS) (Young, 1978) and ≤ 14 points on the Hamilton Depression Rating Scale (HAMD) (Hamilton, 1960).
- Signed informed consent to participate in the study.
Exclusion Criteria:
- Estimated IQ less than 85.
- Any medical condition that may affect neuropsychological performance (such as neurological diseases).
- Presence of any comorbid psychiatric condition (except substance use/abuse).
- Patients who have received any type of psychological intervention in the 6 months prior to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Enhancing cognitive reserve
After the baseline assessment, subjects will be randomly assigned by non-research staff, following the balanced clocks method, to receive a psychological intervention for the improvement of cognitive reserve (N=60) or to the group receiving TAU only (N=60).
All assessments will be common to both groups.
The experimental group will receive an intervention consisting of 12 weekly sessions of approximately 60 minutes duration.
The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning.
Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support.
Patients will also receive pharmacological follow-up in each center.
A psychologist blind to the results of the assessment will provide the therapeutic approach for the improvement of cognitive reserve.
|
Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes.
The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning.
Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support.
Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions.
For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
|
|
Placebo Comparator: Placebo group
This group will receive only pharmacological treatment supervised by the Psychiatrists of each Unit.
|
The group will only receive the pharmacoloical treatment according to the based guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive reserve
Time Frame: one year
|
Assess cognitive reserve, a potential mechanism to cope with brain damage.
Assessed by the Cognitive Reseve Assessment Scale (CRASH), (Amoretti et al, 2019).
The CRASH scale provides a global score and a score for each of the domains that form it (education, occupation, and intellectual and leisure activities).
The scale's maximum total score is 90, and it can be calculated using a formula, created with the intention that all domains have the same weighting in the final score.
The score for each domain is obtained by adding the scores of the items it contains.
For all scores, the higher the result, the better the level of cognitive reserve. .
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive symptoms
Time Frame: one year
|
Assess the clinical state (depressive symptoms) of the patients pre and post intervention. The depressive symptoms will be assessed by the Hamilton Depression Rating Scale (HDRS). For the 17-item version, a score of 0-7 is considered to be normal while a score of 20 or higher (indicating at least moderate severity). The total score ranges from 0 to 52. Each question has between three and five possible answers, with a score of 0-2 or 0-4 respectively. The manic symptoms will be assessed by the Young Mania Rating Scale (YMRS) (Young, 1978) which is a gold-standard clinician-rated assessment tool for severity of manic symptoms. The total YMRS scores ranges from 0 to 60, with higher scores indicating more severe mania. |
one year
|
|
Manic symptoms
Time Frame: one year
|
Assess the severity of manic symptoms of the patients pre and post intervention. The manic symptoms will be assessed by the Young Mania Rating Scale (YMRS) (Young, 1978) which is a gold-standard clinician-rated assessment tool for severity of manic symptoms. The total YMRS scores ranges from 0 to 60, with higher scores indicating more severe mania. |
one year
|
|
Number of participants with subjective cognitive complaints
Time Frame: One year
|
Related cognitive concerns expressed by people with or without objective evidence of cognitive impairment.
It will be assessed by the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) The COBRA utilizes queries informed by everyday mental tasks.
Sixteen items, including verbal learning and memory, executive functionality, attention/concentration, working memory, processing speed, and mental tracking, are used to measure subjective cognitive dysfunction,14 and a four-point scale is used to rate these items (0 = never, 1 = sometimes, '2 = often, and 3 = always).
The total COBRA score is calculated by adding the rating of each item; the highest possible score is 48, and scores of ≥15 indicate moderate to severe subjective cognitive impairment
|
One year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI18/00810
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeWithdrawnBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Vielight Inc.Not yet recruitingBipolar Disorder (BD) | Bipolar | Bipolar Disorder DepressionCanada
-
Xenon Pharmaceuticals Inc.RecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Xenon Pharmaceuticals Inc.Enrolling by invitationBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of Texas Southwestern Medical CenterThe Texas Child Mental Health Care Consortium (TCMHCC)RecruitingBipolar Disorder Family Members | Bipolar Disorder (BD) | Bipolar Disorder I or II | Screening ToolUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati and other collaboratorsRecruitingAdolescents | Bipolar Disorder (BD) | Bipolar Disorder I or II | Bipolar Disorder NOS | Bipolar Spectrum DisorderUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Babes-Bolyai UniversityRecruitingBipolar Disorder (BD)Romania
-
Korea University Anam HospitalHucircadian; Korea University MedicineEnrolling by invitationMood Disorders | Bipolar Disorder (BD) | Depression - Major Depressive Disorder | Depression BipolarSouth Korea
Clinical Trials on Enhancing cognitive reserve
-
Hospital Clinic of BarcelonaInstituto de Salud Carlos III; Institut d'Investigacions Biomèdiques August... and other collaboratorsRecruitingBipolar and Related DisordersSpain
-
Hospital Clinic of BarcelonaRecruitingPsychotic DisorderSpain
-
Indiana UniversityNational Institute on Aging (NIA)CompletedDelirium | Cognitive ImpairmentUnited States
-
Volcano CorporationCompletedCoronary DiseaseBelgium
-
University of DhakaRecruitingDepression | Anxiety | Mental Health | Emotional IntelligenceBangladesh
-
Massachusetts General HospitalCompleted
-
Peking University First HospitalRainmed Ltd., Suzhou, ChinaRecruitingCoronary Artery Disease | Percutaneous Coronary Intervention | Stable Angina Pectoris | Unstable Angina Pectoris | Coronary Stenosis | Acute Myocardial Infarction | Myocardial Ischaemia | Coronary Circulation | Asymptomatic IschemiaChina
-
Cairo UniversityNot yet recruitingCommunity Dwelling Older Adults | Psychological Well-being in Older Adults | Resilience Building Intervention